Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 781–840 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…from 0.4% (2005) to 1.7% (2019). Patients with RA received less LMWH (49% vs. 55%), but more fondaparinux (42% vs. 30%) (both P<0.00…
…npatient CABG recommended at 7 days. All patients admitted with NSTEMI were referred for inpatient CABG as recommended. For isolated o…
…ivariate regression showed no significant difference in whether aspirin, P2Y12 inhibitors, statins, angiotensin-II receptor blockers (A…
…ected quality of life at 3-months (Yes/No survey question, n=30)ILR did not impair quality of life for patients being investigated …
…cess, procedure time, ablation time, fluoroscopy time, and TTI. POLARx demonstrates superior balloon nadir times but is associated wit…
…ommenced initially on diltiazem and with subsequent addition of sildenafil. At 4-month follow-up, CardioMEMS was implanted and macitentan …
…idity and mortality that increase with age. Ketone bodies (KB), acetoacetate and β-hydroxybutyrate, serve as an alternative myocardial energ…
…ns prioritised sodium-glucose co-transporter type 2 inhibitors (SGLT2is) (mean rank: RF: 2.6 (IQR: 2.3–3) vs EU: 2.3 (IQR: 2.2–2.5)), f…
…ve NFY binding elements. One of these compounds (referred to as NFYi-5) significantly inhibited NFY-reporter gene activity, without af…
…ed and downregulated in (A) HCM myofibroblasts with and without SD208 treatment. (B) hiPSC-CM with and without sEV treatment. Several…
…linking mass spectrometry. We also explore the effectiveness of mavacamten as a myosin inhibitor in the presence of specific disease-causi…
…ed by qRT-PCR and immunofluorescence. TGF-β1 receptor inhibitor SD208 (3 μM) treatment exerted antifibrotic effects, reducing the exp…